Table 3.
Preclinical studies clearing senescent immune and stromal cells within the tumor microenvironment.
| Target | Treatment | Condition | Outcome | Reference |
|---|---|---|---|---|
| Neutrophil | 3MRp16 model with ganciclovir suicide gene strategy | Prostate cancer | Suppressed tumor growth | 107 |
| Procyanidin C1 | Melanoma | Reduced tumor metastasis and restored T cell responses | 128 | |
| Macrophage | Diphtheria toxin targeting tagged cells | Lung cancer | Diminished lung tumor burden and prolonged survival | 23 |
| ABT-737 | ||||
| ABT-263 | Lung cancer | Suppressed early tumorigenesis | 138 | |
| ABT-263 | Colon cancer | Restored CD8+ T cell proliferation and response to immunotherapy | 19 | |
| Nicotinamide mononucleotide | Glioblastoma | Inhibited T-cell dysfunction and delayed tumor initiation | 133 | |
| IL-4 | Aging | Improved the health span of aged mice | 335 | |
| T cell | Metformin | NA | Lowered IFN-γ and IL-6 and increased TNF-α production | 283 |
| CD153-CpG vaccine | Obesity | Improved obesity-induced metabolic disorders | 333 | |
| Endothelial cell | Anti-Notch1/ VCAM1 antibody | Ovarian cancer | Reduced tumor cell adhesion and lowered lung metastasis | 252 |
| GPNMB vaccine | Atherosclerosis | Improved metabolic disorders | 334 | |
| Fibroblast | ABT-199 | Pancreatic cancer | Restored CD8+ T cell function and response to immunotherapy | 236 |
| ABT-737 | Breast cancer | Enhanced NK cell function and infiltration | 263 | |
| Anti-TSPAN8 antibody | Breast cancer | Resensitize the response to chemotherapy | 237 | |
| Q | Osteosarcoma | Reduced tumor invasiveness | 303 | |
| D plus Q | Ovarian cancer | Reduced tumor metastasis | 304 |
D, dasatinib; Q, quercetin; GPNMB, glycoprotein nonmetastatic melanoma protein B.